Systemic and targeted therapy for advanced colon cancer

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 1, 2008, Pages 135-149

  Hegde, Sanjay R ^a   Sun, Weijing ^a   Lynch, John P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bevacizumab; Cetuximab; Chemotherapy; Fluorouracil; Innotecan; Metastatic colon cancer; Oxaliplatin; Panitumumab; Targeted therapy

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; DIPHENHYDRAMINE; ELOTAXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; ORZEL; OXALIPLATIN; PANITUMUMAB; PLACEBO; PROTEASOME INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TEGAFUR; UFT; UNINDEXED DRUG; VATALANIB;

ADVANCED CANCER; ALOPECIA; ANGINA PECTORIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTERY EMBOLISM; BLEEDING; BLINDNESS; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; BRAIN EDEMA; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLITIS; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COUGHING; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPEPSIA; FATIGUE; GASTROINTESTINAL TOXICITY; GILBERT DISEASE; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; LIVER METASTASIS; LIVER RESECTION; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPH NODE METASTASIS; MENTAL FUNCTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OTOTOXICITY; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PROGNOSIS; PROTEINURIA; REPEATED DRUG DOSE; REVIEW; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TINGLING; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VISUAL IMPAIRMENT; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS;

EID: 49149094340     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.1.135     Document Type: Review

References (117)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476-487 (2005).
3. Greene FL, Page DI, Fleming ID et al. In: AJCC Cancer Staging Manual (6th Edition). Springer, New York, NY, USA (2002).
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the New American Joint Committee On Cancer Sixth Edition Staging. J. Natl Cancer Inst. 96(19), 1420-1425 (2004).
5. Scheitauer W RH, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care alone in patients with metastatic colorectal cancer. BMJ 306, 752-755 (1993).
6. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138), 1413-1418 (1998).
7. Best PS, C Baughan, R Buchanan et al. Colorectal Meta-analysis Collaboration. Palliative chemotherapy for advanced or metastatic colorectal caricer. Cochrane Database Syst. Rev. 1, CD001545 (2000).
8. Sobrero A GA, Grossi F, Puglisi F et al. Mechanism of action of flouropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin. Oncol. 27(Suppl. 10), 72-77 (2000).
9. Zhang ZG HA, Rustum YM. Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. Semin. Oncol. 19(Suppl. 3), 10-15 (1992).
10. van Kuilenburg ABP, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dihydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of die common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res. 7(5), 1149-1153 (2001).
11. The Meta-Analysis Group in C. Modulation of fluorouraril by leucovorin in patients with advanced colorectal cancer an updated meta-analysis. J. Clin. Oncol. 22(18), 3766-3775 (2004).
12. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 356(9227), 373-378 (2000).
13. Hahn, RG, Moertel CG, Schutt AJ et al. A double-blind comparison of intensive course 5-fluorouracil by oral vs intravenous route in the treatment of colorectal carcinoma. Cancer 35(4), 1031-1035 (1975).
14. Pentheroudakis G TC. The rational development of capecitabine fiorn the laboratory to the clinic. Anti Cancer Res. 22, 3589-3596 (2002).
15. Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur. J. Cancer 34(10), 1509-1513 (1998).
16. Sulkes A, Benner SE, Catietta RM. Uracilftorafur: an oral fluoropyrimidine active in colorectal cancer. J. Clin. Oncol. 16(10), 3461-3475 (1998).
17. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 45(4), 291-297 (2000).
18. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol. 19(21), 4097-4106 (2001).
19. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19(8), 2282-2292 (2001).
20. Mayer RJ. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J. Clin. Oncol. 19(21), 4093-4096 (2001).
21. Cassidy J, Twelves C, Van Cutsern E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol. 13(4), 566-575 (2002).
22. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20(17), 3617-3627 (2002).
23. Douillard J-Y, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20(17), 3605-3616 (2002).
24. Raymond E FS, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25, 4-12 (1998).
25. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel. Biochem. Pharmacol. 52(12), 1855-1865 (1996).
26. Raymond E B-FC, Djelloul S et al. Antitiumor activity of oxaliplatin in combination with 5-fluorouracil-leucovorin and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs 8, 876-885 (1997).
27. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. 21(11), 2059-2069 (2003).
28. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000).
29. Raymond E, Faivre S, Chaney S, Woynarowski J et al. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 1(3), 227-235 (2002).
30. A. G. Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol. 30, 5-13 (2003).
31. Armand JP BV, Raymond E et al. Oxaliplatin in colorectal cancer: an overview. Semin. Oncol. 5(Suppl. 10), 96-104 (2000).
32. Becouarn Y, Ychou M, Ducreux M et al. Phase II trial of oxatiplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol. 16(8), 2739-2744 (1998).
33. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18(1), 136- (2000).
34. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FLD/folinic acid (FA) (Mayo) vs weekly high dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 512).
35. Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Cancer 104(2), 282-289 (2005).
36. Porschen R, Arkenau H-T, Kubicka S et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer - a final report of the AIO Colorectal Study Group. J. Clin. Oncol. (2007) (Epub ahead of print).
37. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin versus continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J. Clin. Oncol. 25, 4224-4230 (2007).
38. Iyer L RM. Clinical pharmacology of camptothecins. Cancer Chemother. Pharmacol. 42(0), S31-S43 (1998).
39. Mathijssen RHJ, van Alphen RJ, Verweij J et al. Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11). Clin. Cancer Res. 7(8), 2182-2194 (2001).
40. Iyer L, Das S, Janisch L et al. UGTIA1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002).
41. Ando Y, Saka H, Asai G et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol. 9(8), 845-847 (1998).
42. Innocenti F, Undevia SD, Iyer L et al. Genetic Variants in the UDP-glucuronosyltransferase 1a1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8),1382-1388 (2004).
43. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138), 1407-1412 (1998).
44. Michael M HD, Oza A, et al. The palliative benefit of irino,tecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. Clin. Colorectal Cancer 2, 93-101 (2002).
45. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-fine treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209), 1041-1047 (2000).
46. Tournigand C, Andre T, Achille E et al. FOLFIRI Followed by FOLFOX6 or tile reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J. Clin. Oncol. 22(2), 229-237 (2004).
47. C. Fuchs JM, E. Mitchell, R. Wierzbicki et al. A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24(18 Suppl.) (2006) (Abstract 3506).
48. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343(13), 905-914 (2000).
49. Delaunoit R GR, Sargent DJ et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer 101 (10), 2170-2176 (2004).
50. Sargent DJ ND, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N. Engl. J. Med. 345 (2), 144-145 (2001).
51. Goldberg RM, Sargent DI, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22(1), 23-30 (2004).
52. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23(22), 4866-4875 (2005).
53. Grothey A, Jordan K, Kellner O et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-fine therapy of advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol. 22, 255 (2003) (Abstract 1022).
54. Vauthey J-N, Pawlik TM, Ribero D et al. chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 24(13), 2065-2072 (2006).
55. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22(7), 1209-1214 (2004).
56. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J. Clin. Oncol. 23(36), 9441-9442 (2005).
57. Lynch JP, Rustgi AK. Mechanisms of GI malignancies. In: Physiology of the Gastrointestinal Tract. Johnson L (Ed). Elsevier, CA, USA (2004).
58. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70. (2000).
59. Folkinan J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6(4), 273-286 (2007).
60. Easwaran V, Lee SH, Inge L et al. β-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 63(12), 3145-3153 (2003).
61. Gerber H-P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoyic therapy in preclinical studies. Cancer Res. 65(3), 671-680 (2005).
62. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21(1), 60-65 (2003).
63. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
64. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
65. Cassidy J, Clarke S, Diaz-Rub E et al. XELOX vs FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer (MCRC). J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 4030).
66. Saltz L, Clarke S, Diaz-Ru E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 4028).
67. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99(16), 1232-1239 (2007).
68. Los M, Roodhart JM, Voest EE. Target practice: lessons from Phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12(4), 443-450 (2007).
69. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch. Neurol. 63(10), 1475-1478 (2006).
70. Goldberg RM. Cetuximab. Nat. Rev. Drug Discov. (Suppl.), S10-11 (2005).
71. Kopp R, Rothbauer E, Ruge M et al. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res. 162, 115-132 (2003).
72. Galizia G, Lieto E, Ferraraccio F et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann. Surg. Oncol. 13(6), 823-835 (2006).
73. Saltz LB, Meropol NJ, Loehrer PJ Sr. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
74. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
75. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24(30), 4914-4921 (2006).
76. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803-1810 (2005).
77. Van Cutsem E, Nowacki M, La I et al. Randomized Phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 4000).
78. Bokemeyer C, Bondarenko I, Makhs A et al. Cetuyimab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized Phase II study. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(18 Suppl.) 4035, (2007).
79. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin. Drug Saf. 6(2), 175-182 (2007).
80. Tejpar S, Peeters M, Humb Y et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal. cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(18 Suppl.) 4037, (2007).
81. Saltz LB, Lenz H-J, Kindler HL et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25(29), 4557-4561 (2007).
82. Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658-1664 (2007).
83. Van Cutsem E, Siena S, Humblet Y et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann. Oncol. 19(1), 92-98 (2007).
84. Baselga J, Tabernero J. Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet. J. Clin. Oncol. 25(29), 4516-4518 (2007).
85. Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin. Cancer Res. 12(24), 7222-7231 (2006).
86. Braun AH, Stark K, Dirsch O et al. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs 16(10), 1099-1108 (2005).
87. Fichera A, Little N, Jagadeeswaran S et al. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res. 67(2), 827-835 (2007).
88. Kuo T, Cho CD, Halsey J et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol. 23(24), 5613-5619 (2005).
89. Blanke CD. Gefitinib in colorectal cancer: if wishes were horses. J. Clin. Oncol. 23(24), 5446-5449 (2005).
90. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N. Engl. J. Med. 357(3), 258-265 (2007).
91. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25(7), 884-896 (2007).
92. Stahtea XN, Roussidis AE, Kanakis I et al. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int. J. Cancer (2007).
93. Kitadai Y, Sasaki T, Kuwai T et al. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am. J. Pathol. 169(6), 2054-2065 (2006).
94. Marzola P, Degrassi A, Calderan L et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin. Cancer Res. 11(16), 5827-5832 (2005).
95. Morimoto AM, Tan N, West K et al. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 23(8), 1618-1626 (2004).
96. Saltz LB RL, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 25 (30), 4793-4799 (2007).
97. Kohne C, Bajetta E, Lin E et al. Final results of CONFIRM 2: a multinational, randomized, double-blind, Phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRQ receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. Proccedings of the 2007 ASCO Annual Meeting. J. Clin. Oncol. 25(18 Suppl.), 4033 (2007).
98. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur. J. Cancer 43(7), 1125-1133 (2007).
99. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5(1), 18 (2005).
100. Zhu H, Guo W, Zhang L et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol. Ther. 4(7), 791-786 (2005).
101. Cusack JC, Jr, Liu R, Xia L et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res. 12(22), 6758-6764 (2006).
102. Watanabe T, Wu T-T, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344(16), 1196-1206 (2001).
103. Genuardi M, Viel A, Bonora D et al. Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal. cancer susceptibility. Hum. Genet. 102(1), 15-20 (1998).
104. de la Chapelle A. Microsatellite instability. N. Engl. J. Med. 349(3), 209-210 (2003).
105. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003).
106. Vogelstein B FE, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319 (9), 525-532 (1988).
107. Ookawa K SM, Hiroshi S et al. Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Int. J. Cancer 53 (3), 385-387 (1993).
108. Cho KR FE. DCC: linking tumor suppressor genes and altered cell surface interactions in cancer? Curr. Opin. Genet. Dev. 5(1), 72-78 (1995).
109. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J. Med. 331(4), 213-221 (1994).
110. Ogunbiyi OA, Goodfellow PJ, Herfarth K et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J. Clin. Oncol. 16(2), 427-433 (1998).
111. Liersch T, Langer C, Ghadimi BM et al. Lymph node status and TS gene expression are prognostic markers in Stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J. Clin. Oncol. 24(25), 4062-4068 (2006).
112. Prcolo VE F S, Hansen K et al. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch. Surg. 132 (4), 371-375 (1997).
113. Ahnen DJ, Feigl P, Quan G et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 58(6), 1149-1158 (1998).
114. Barrier A, Roser F, Boelle PY et al. Prognosis of Stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26 (18), 2642-2648 (2006).
115. Zhao Z XY, Elson P et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J. Clin. Oncol. 25(19), 2696-2701 (2007).
116. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras Mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007).
117. Benson AB, III. New approaches to assessing and treating early-stage colon and rectal cancers: Cooperative Group strategies for assessing optimal approaches in early-stage disease. Clin. Cancer Res. 13(22), 6913-6920 (2007).